Doctors typically consider these medications only after other approaches such as nutrition changes, increased physical activity, and behavioral support have not been enough
Gastrointestinal adverse events were reported in 62% of the group taking semaglutide, compared to 42% in the placebo group.[ref] Bigger picture of GLP-1 in the rise of obesity: Several recent studies shed light on how environmental factors may be causing a decrease in GLP-1 levels
Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway
Dose Communication Please keep your provider in the loop about fatigue, especially after adjusting your retatrutide dose
Other contemporary studies, such as the EXSCEL and FREEDOM trials evaluated the cardiovascular effects of exenatide, a GLP-1 RA (80, 81)
While weight loss drugs could still be viable option for you, either alone or in conjunction with weight loss surgery, its important to have a individualized tailored approach and consider long term outcomes